NCT01989585 2026-04-13
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
16 trialsNCT04557956 2026-04-02
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04201457 2026-02-03
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
Pediatric Brain Tumor Consortium
Phase 1/2 Active not recruiting
NCT05585320 2025-09-02
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Immuneering Corporation
Phase 1/2 Active not recruiting
NCT06712875 2025-05-29
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2 Recruiting
NCT01902173 2025-01-14
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02872259 2025-01-14
BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Haukeland University Hospital
Phase 1/2 Completed
NCT02392871 2024-11-27
CombiRT
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Completed
NCT03455764 2024-07-31
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT02143050 2023-11-18
Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
University of Louisville
Phase 1/2 Withdrawn
NCT02130466 2022-08-01
MK-3475-022
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT01677741 2021-11-24
A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
Novartis
Phase 1/2 Completed
NCT01750918 2021-10-29
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Novartis
Phase 1/2 Completed
NCT02124772 2021-07-14
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Novartis
Phase 1/2 Completed
NCT03754179 2021-04-28
COMBI-R2
Universitair Ziekenhuis Brussel
Phase 1/2 Unknown
NCT03391050 2019-07-31
A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma
Aprea Therapeutics
Phase 1/2 Terminated